丽珠集团：阿立哌唑微球挂网价已公布

Core Viewpoint - Lijun Group (000513) announced on October 27 that it is actively advancing the national negotiation process for the pricing of Aripiprazole microspheres, expecting results within the year, indicating significant future sales potential for long-acting psychiatric products in China [1] Group 1: Market Potential - The penetration rate of long-acting psychiatric formulations in China is currently low, with the clinical usage rate of long-acting antipsychotic injections being less than 1%, compared to an average usage rate of 25%-30% in Europe and the U.S. [1] - The company has initiated various market preparation activities for Aripiprazole microspheres, including forming a nationwide team covering key departments [1] Group 2: Research and Evidence - A real-world evidence study has been launched, covering 60 centers and involving 1,200 patients, to accumulate clinical evidence for Chinese patients [1] - The "Psychiatric Expert Says" column has seen significant growth in followers, effectively reaching different groups from doctors to patients [1] Group 3: Future Outlook - If the national negotiation is successful, it will provide strong support for the volume release of Aripiprazole microspheres and promote the continuous expansion of the long-acting psychiatric formulation market [1]